Drug Profile

ARTS 011

Alternative Names: ARTS-011

Latest Information Update: 29 Jul 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Allorion Therapeutics
Class Anti-inflammatories; Antipsoriatics; Small molecules
Mechanism of Action TYK2 kinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Autoimmune disorders

Most Recent Events

28 Mar 2024 Allorion Therapeutics completes a phase I trial in Autoimmune disorders (In volunteers) in China (PO) (NCT06260527)
30 Aug 2023 Phase-I clinical trials in Autoimmune disorders (In volunteers) in China (PO) (NCT06260527)
31 Dec 2022 Allorion Therapeutics files an IND application with the NMPA in China for autoimmune disorders, prior to December 2022 (Allorion Therapeutics pipeline, March 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com